NCT02766699 (CerebralEDV) is a Phase 1 clinical trial of EGFR(V)-EDV-Dox in Glioblastoma, sponsored by Engeneic Pty Limited.

Who is sponsoring NCT02766699?

NCT02766699 is sponsored by Engeneic Pty Limited.

What drugs are being tested in NCT02766699?

Interventions in NCT02766699: EGFR(V)-EDV-Dox.

What condition does NCT02766699 study?

NCT02766699 studies Glioblastoma, Astrocytoma, Grade IV.

Is NCT02766699 still recruiting?

NCT02766699 is currently completed. Last updated 3 June 2025.

Last reviewed 2025-06-03 · How we verify

NCT02766699: CerebralEDV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Completed Phase 1 Last updated 3 June 2025

What this trial tests

Phase 1 trial testing EGFR(V)-EDV-Dox in Glioblastoma in 9 participants. Completed in 30 March 2022.

Timeline

25 October 2016

Primary endpoint
21 August 2021

30 March 2022

Quick facts

Lead sponsor	Engeneic Pty Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	25 October 2016
Primary completion	21 August 2021
Estimated completion	30 March 2022
Sites	2 locations across United States

Drugs / interventions tested

EGFR(V)-EDV-Dox — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Astrocytoma, Grade IV — all drugs for Astrocytoma, Grade IV →

Sponsor

Engeneic Pty Limited — full company profile →

Who can join

18 and older, any sex, with Glioblastoma or Astrocytoma, Grade IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of patients with recurrent glioblastoma multiforme (GBM).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in the clinic: An update.
Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskilsson E, Røsland GV, Solecki G, Wang Q, et al · · 2018 · cited 228× · PMID 29040782 · DOI 10.1093/neuonc/nox191
Drug delivery to the central nervous system.
Nance E, Pun SH, Saigal R, Sellers DL. · · 2022 · cited 224× · PMID 38464996 · DOI 10.1038/s41578-021-00394-w
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
A Critical Overview of Targeted Therapies for Glioblastoma.
Jain KK. · · 2018 · cited 161× · PMID 30374421 · DOI 10.3389/fonc.2018.00419
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
Recent advances of bispecific antibodies in solid tumors.
Yu S, Li A, Liu Q, Yuan X, et al · · 2017 · cited 114× · PMID 28931402 · DOI 10.1186/s13045-017-0522-z

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02766699 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Engeneic Pty Limited
Last refreshed: 3 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02766699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing